摘要
Background:The real-world study on efficacy and safety of dupilumab in chronic obstructive pulmonary disease(COPD)with type 2 inflammation are scarce.Our objective was to assess the impact of dupilumab in such patients within a real-world setting.Methods:Seventeen patients with COPD and type 2 inflammation,who underwent triple inhaled therapy in conjunction with dupilumab from January 2020 to October 2023,comprised the research group.Similarly,another 17 patients with COPD and type 2 inflammation,who received only triple inhaled therapy,were included in the control group.After a six-month treatment period,pulmonary function tests,type 2 inflammatory marker levels,and quality of life assessments were compared between the two groups to evaluate the effectiveness of dupilumab in combination with triple inhaled therapy for COPD with type 2 inflammation.Results:Following treatment,the research group exhibited significant improvements in forced expiratory volume in 1 s(FEV1)and forced expiratory flow between 25%and 75%of forced vital capacity(FVC)compared to the control group(P<0.05).Notably,the FEV1 and FVC values of the research group were also notably superior to those of the control group post-treatment(P<0.05).Additionally,the research group demonstrated a statistically significant enhancement in COPD Assessment Test scores after treatment(P<0.05).Conclusion:The combination of dupilumab with triple inhaled therapy has been shown to enhance pulmonary function,decrease immunoglobulin E levels,manage airway inflammation,and elevate the quality of life of patients with COPD and type 2 inflammation.
